Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Journal of Translational Medicine

Figure 2

From: In vivo evidence of htid suppressive activity on ErbB-2 in breast cancers over expressing the receptor

Figure 2

Comparative analysis of h tid and HER-2 expression in breast and non breast tumors. The detection of htid was performed as described in the legend to Figure 1. The ErbB-2 oncogene was detected using a monoclonal anti ErbB-2 antibody (AO485). Weak htid expression is detectable in HER-2 over expressing breast tumors of the luminal B (A, B) and HER-2 (C, D) subtype as well as in a renal clear cell carcinoma (E, F). (Original magnification: 250×).

Back to article page